| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Taiwan | 24 | 2025 | 62 | 1.830 |
Why?
|
| Genome-Wide Association Study | 15 | 2024 | 1878 | 1.400 |
Why?
|
| Lung Neoplasms | 13 | 2024 | 1787 | 1.340 |
Why?
|
| Breast Neoplasms | 18 | 2025 | 2771 | 1.310 |
Why?
|
| Biomarkers, Tumor | 14 | 2025 | 1721 | 1.100 |
Why?
|
| DNA Methylation | 9 | 2025 | 1147 | 1.020 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2024 | 2941 | 0.960 |
Why?
|
| Criminals | 2 | 2021 | 20 | 0.910 |
Why?
|
| Adenocarcinoma | 5 | 2020 | 1071 | 0.810 |
Why?
|
| Brugada Syndrome | 5 | 2024 | 12 | 0.790 |
Why?
|
| Gene Expression Profiling | 13 | 2025 | 1923 | 0.740 |
Why?
|
| Cellular Senescence | 1 | 2023 | 201 | 0.730 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 738 | 0.710 |
Why?
|
| Methamphetamine | 1 | 2021 | 48 | 0.710 |
Why?
|
| Research Design | 2 | 2015 | 748 | 0.700 |
Why?
|
| Transcriptome | 10 | 2025 | 1137 | 0.640 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2669 | 0.630 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2020 | 154 | 0.600 |
Why?
|
| Genetic Markers | 4 | 2019 | 633 | 0.590 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 272 | 0.590 |
Why?
|
| DNA Copy Number Variations | 7 | 2022 | 1025 | 0.580 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 702 | 0.570 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 236 | 0.570 |
Why?
|
| Humans | 92 | 2025 | 134083 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2025 | 3495 | 0.570 |
Why?
|
| Exome | 1 | 2022 | 1075 | 0.560 |
Why?
|
| Drosophila melanogaster | 1 | 2023 | 844 | 0.550 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 287 | 0.550 |
Why?
|
| MicroRNAs | 3 | 2022 | 951 | 0.550 |
Why?
|
| Prognosis | 18 | 2025 | 5086 | 0.540 |
Why?
|
| Computational Biology | 6 | 2023 | 888 | 0.530 |
Why?
|
| Aging | 2 | 2023 | 1306 | 0.520 |
Why?
|
| Neoplasm Staging | 9 | 2024 | 1391 | 0.500 |
Why?
|
| Middle Aged | 36 | 2025 | 29394 | 0.480 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 1007 | 0.460 |
Why?
|
| Registries | 6 | 2025 | 1578 | 0.450 |
Why?
|
| Female | 53 | 2025 | 71892 | 0.440 |
Why?
|
| Chymotrypsin | 1 | 2014 | 17 | 0.440 |
Why?
|
| Endothelial Growth Factors | 1 | 2014 | 54 | 0.430 |
Why?
|
| Nucleus Accumbens | 2 | 2025 | 55 | 0.430 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 377 | 0.430 |
Why?
|
| Precision Medicine | 2 | 2021 | 357 | 0.420 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 757 | 0.420 |
Why?
|
| Adult | 34 | 2025 | 31930 | 0.410 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1417 | 0.410 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 468 | 0.400 |
Why?
|
| Coronary Vessels | 1 | 2017 | 567 | 0.390 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2023 | 75 | 0.390 |
Why?
|
| Microbiota | 3 | 2023 | 443 | 0.390 |
Why?
|
| Carrier Proteins | 2 | 2017 | 1075 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1317 | 0.370 |
Why?
|
| SEER Program | 3 | 2021 | 224 | 0.370 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 384 | 0.370 |
Why?
|
| Aged | 25 | 2025 | 21772 | 0.360 |
Why?
|
| Proportional Hazards Models | 4 | 2024 | 1488 | 0.360 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2022 | 1071 | 0.360 |
Why?
|
| Membrane Proteins | 5 | 2021 | 1613 | 0.350 |
Why?
|
| Computer Simulation | 3 | 2022 | 707 | 0.350 |
Why?
|
| Case-Control Studies | 8 | 2024 | 3667 | 0.340 |
Why?
|
| Thymoma | 2 | 2021 | 21 | 0.340 |
Why?
|
| Whole Genome Sequencing | 3 | 2025 | 324 | 0.330 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 822 | 0.320 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 894 | 0.320 |
Why?
|
| Tumor Microenvironment | 3 | 2025 | 698 | 0.320 |
Why?
|
| Mammography | 3 | 2025 | 133 | 0.320 |
Why?
|
| Male | 29 | 2025 | 66092 | 0.300 |
Why?
|
| Schizophrenia | 2 | 2025 | 332 | 0.300 |
Why?
|
| ADAM Proteins | 3 | 2021 | 87 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 1833 | 0.290 |
Why?
|
| Pneumonectomy | 4 | 2023 | 148 | 0.280 |
Why?
|
| Survival Analysis | 5 | 2024 | 1599 | 0.270 |
Why?
|
| DNA, Mitochondrial | 2 | 2025 | 244 | 0.260 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 112 | 0.260 |
Why?
|
| Tauopathies | 2 | 2025 | 78 | 0.250 |
Why?
|
| Prefrontal Cortex | 2 | 2025 | 218 | 0.250 |
Why?
|
| Retrospective Studies | 15 | 2025 | 17538 | 0.240 |
Why?
|
| Algorithms | 6 | 2023 | 1735 | 0.240 |
Why?
|
| Genome, Human | 4 | 2021 | 1344 | 0.240 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 399 | 0.240 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2022 | 406 | 0.230 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2025 | 66 | 0.230 |
Why?
|
| Paternal Age | 1 | 2025 | 17 | 0.230 |
Why?
|
| Pancreas | 2 | 2023 | 232 | 0.230 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2024 | 807 | 0.230 |
Why?
|
| Tourniquets | 1 | 2024 | 12 | 0.220 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2024 | 62 | 0.220 |
Why?
|
| Metals, Heavy | 1 | 2024 | 23 | 0.220 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2023 | 57 | 0.220 |
Why?
|
| Early Detection of Cancer | 2 | 2025 | 414 | 0.220 |
Why?
|
| Mesenchymoma | 1 | 2023 | 2 | 0.210 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2023 | 23 | 0.210 |
Why?
|
| Paranasal Sinuses | 1 | 2023 | 19 | 0.210 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 127 | 0.210 |
Why?
|
| Hypertriglyceridemia | 1 | 2024 | 114 | 0.210 |
Why?
|
| Atlases as Topic | 1 | 2023 | 17 | 0.210 |
Why?
|
| Puberty, Precocious | 1 | 2023 | 29 | 0.210 |
Why?
|
| Amyloid beta-Peptides | 1 | 2025 | 246 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 2137 | 0.210 |
Why?
|
| Vascular System Injuries | 1 | 2024 | 60 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2022 | 972 | 0.200 |
Why?
|
| DNA | 4 | 2021 | 1681 | 0.200 |
Why?
|
| Pancreatic Fistula | 1 | 2023 | 30 | 0.200 |
Why?
|
| Genetic Association Studies | 3 | 2022 | 854 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2022 | 2044 | 0.200 |
Why?
|
| Alcohol Drinking | 1 | 2025 | 387 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2015 | 505 | 0.200 |
Why?
|
| tau Proteins | 1 | 2025 | 240 | 0.200 |
Why?
|
| Genome | 2 | 2023 | 528 | 0.190 |
Why?
|
| Genetics, Population | 1 | 2023 | 198 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2023 | 93 | 0.190 |
Why?
|
| Diploidy | 1 | 2022 | 39 | 0.190 |
Why?
|
| Leiomyosarcoma | 1 | 2022 | 30 | 0.190 |
Why?
|
| Harm Reduction | 1 | 2021 | 12 | 0.190 |
Why?
|
| Hyperkalemia | 1 | 2023 | 71 | 0.190 |
Why?
|
| Environmental Exposure | 1 | 2024 | 246 | 0.190 |
Why?
|
| Semaphorins | 1 | 2022 | 33 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 128 | 0.190 |
Why?
|
| Carcinoma, Papillary | 1 | 2022 | 96 | 0.190 |
Why?
|
| Forests | 1 | 2021 | 15 | 0.180 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2023 | 97 | 0.180 |
Why?
|
| Toxins, Biological | 1 | 2022 | 71 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 549 | 0.180 |
Why?
|
| Nanotechnology | 1 | 2021 | 52 | 0.180 |
Why?
|
| Thymus Neoplasms | 1 | 2021 | 40 | 0.180 |
Why?
|
| Archaea | 1 | 2021 | 13 | 0.180 |
Why?
|
| Molecular Sequence Annotation | 2 | 2019 | 163 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2021 | 100 | 0.180 |
Why?
|
| Recidivism | 1 | 2020 | 7 | 0.180 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 407 | 0.180 |
Why?
|
| Neoplasm Proteins | 3 | 2024 | 718 | 0.180 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 3 | 2020 | 40 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 225 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2025 | 834 | 0.170 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2020 | 24 | 0.170 |
Why?
|
| Metagenomics | 1 | 2021 | 110 | 0.170 |
Why?
|
| Neurogenesis | 1 | 2022 | 223 | 0.170 |
Why?
|
| Bacteria | 2 | 2022 | 537 | 0.170 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 212 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 266 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 56 | 0.160 |
Why?
|
| Software | 2 | 2023 | 733 | 0.160 |
Why?
|
| Glutathione Transferase | 1 | 2020 | 163 | 0.160 |
Why?
|
| Quinolines | 1 | 2020 | 114 | 0.160 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 12 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 250 | 0.160 |
Why?
|
| Animals | 11 | 2025 | 36545 | 0.160 |
Why?
|
| Disease Eradication | 1 | 2019 | 39 | 0.160 |
Why?
|
| Drug Resistance, Microbial | 1 | 2019 | 198 | 0.160 |
Why?
|
| Allergens | 1 | 2021 | 278 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 331 | 0.150 |
Why?
|
| Gene Dosage | 2 | 2022 | 458 | 0.150 |
Why?
|
| Gene Fusion | 1 | 2019 | 61 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 298 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 358 | 0.150 |
Why?
|
| Antigens, CD | 2 | 2018 | 451 | 0.150 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2018 | 39 | 0.150 |
Why?
|
| Datasets as Topic | 2 | 2019 | 105 | 0.150 |
Why?
|
| Galliformes | 1 | 2018 | 1 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 189 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 872 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2023 | 962 | 0.150 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 330 | 0.150 |
Why?
|
| Biomarkers | 3 | 2024 | 3434 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 277 | 0.140 |
Why?
|
| Angiopoietin-2 | 1 | 2017 | 16 | 0.140 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2017 | 10 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 1409 | 0.140 |
Why?
|
| Latent Tuberculosis | 1 | 2018 | 76 | 0.140 |
Why?
|
| Neoplasms | 3 | 2022 | 3037 | 0.140 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 54 | 0.140 |
Why?
|
| Cadherins | 1 | 2018 | 186 | 0.140 |
Why?
|
| Disease | 1 | 2019 | 133 | 0.140 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 331 | 0.140 |
Why?
|
| Proteome | 1 | 2019 | 281 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 880 | 0.140 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2017 | 6 | 0.140 |
Why?
|
| Receptor, Notch4 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 830 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2021 | 5217 | 0.140 |
Why?
|
| Immunohistochemistry | 4 | 2025 | 1765 | 0.140 |
Why?
|
| Hypertension | 2 | 2023 | 1398 | 0.130 |
Why?
|
| Eye Proteins | 1 | 2018 | 234 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2019 | 399 | 0.130 |
Why?
|
| Ketamine | 1 | 2020 | 226 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 370 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 55 | 0.130 |
Why?
|
| Genotype | 5 | 2023 | 2811 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 604 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 93 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2019 | 624 | 0.130 |
Why?
|
| Sarcoma | 1 | 2019 | 209 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2017 | 146 | 0.130 |
Why?
|
| Hippocampus | 1 | 2022 | 863 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 121 | 0.130 |
Why?
|
| Adenosarcoma | 1 | 2016 | 1 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.130 |
Why?
|
| Chromothripsis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 477 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 947 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 289 | 0.130 |
Why?
|
| Databases, Genetic | 1 | 2019 | 504 | 0.130 |
Why?
|
| Mullerian Ducts | 1 | 2016 | 43 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 475 | 0.120 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 3796 | 0.120 |
Why?
|
| Therapeutics | 1 | 2015 | 8 | 0.120 |
Why?
|
| Biostatistics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 365 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2023 | 793 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2015 | 60 | 0.120 |
Why?
|
| Genetic Loci | 1 | 2017 | 367 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 510 | 0.120 |
Why?
|
| Phenotype | 6 | 2023 | 4570 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 142 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 915 | 0.120 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 86 | 0.120 |
Why?
|
| Proteomics | 1 | 2019 | 598 | 0.120 |
Why?
|
| Sample Size | 1 | 2015 | 88 | 0.120 |
Why?
|
| Shab Potassium Channels | 1 | 2014 | 5 | 0.120 |
Why?
|
| Epithelial Sodium Channels | 1 | 2014 | 16 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2017 | 214 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 446 | 0.110 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 102 | 0.110 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2014 | 39 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2016 | 248 | 0.110 |
Why?
|
| Plasminogen Activators | 1 | 2014 | 21 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 396 | 0.110 |
Why?
|
| Evolution, Molecular | 1 | 2018 | 710 | 0.110 |
Why?
|
| EGF Family of Proteins | 1 | 2014 | 14 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 46 | 0.110 |
Why?
|
| Japan | 2 | 2024 | 155 | 0.110 |
Why?
|
| Tetraspanins | 1 | 2014 | 31 | 0.110 |
Why?
|
| Risk Factors | 6 | 2025 | 11180 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 239 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2022 | 2562 | 0.110 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 48 | 0.110 |
Why?
|
| Models, Biological | 1 | 2019 | 1539 | 0.110 |
Why?
|
| Potassium Channels | 1 | 2014 | 166 | 0.110 |
Why?
|
| Epigenesis, Genetic | 3 | 2025 | 773 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 3742 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 168 | 0.100 |
Why?
|
| Reference Standards | 1 | 2014 | 247 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 723 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2019 | 1719 | 0.100 |
Why?
|
| Multifactorial Inheritance | 2 | 2024 | 167 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7216 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 5477 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2017 | 375 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2023 | 4934 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 337 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2018 | 553 | 0.100 |
Why?
|
| Prevalence | 2 | 2019 | 2684 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1347 | 0.090 |
Why?
|
| Mutation | 6 | 2025 | 6316 | 0.090 |
Why?
|
| Patient Selection | 1 | 2015 | 735 | 0.090 |
Why?
|
| Mastectomy, Segmental | 2 | 2023 | 40 | 0.090 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2023 | 106 | 0.090 |
Why?
|
| Siblings | 2 | 2025 | 199 | 0.090 |
Why?
|
| Decision Making | 1 | 2015 | 700 | 0.080 |
Why?
|
| Logistic Models | 1 | 2015 | 1909 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3999 | 0.080 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 1335 | 0.080 |
Why?
|
| Age of Onset | 2 | 2025 | 637 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2019 | 1278 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2022 | 259 | 0.080 |
Why?
|
| Mice | 6 | 2025 | 19047 | 0.080 |
Why?
|
| CpG Islands | 2 | 2024 | 347 | 0.080 |
Why?
|
| A549 Cells | 2 | 2021 | 49 | 0.080 |
Why?
|
| Survival Rate | 2 | 2024 | 2218 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2020 | 333 | 0.080 |
Why?
|
| Inflammation | 1 | 2017 | 1594 | 0.080 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 41 | 0.080 |
Why?
|
| Liver | 1 | 2016 | 1879 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2025 | 2539 | 0.070 |
Why?
|
| Genomics | 3 | 2021 | 1673 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 675 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1165 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2023 | 13073 | 0.070 |
Why?
|
| Mass Screening | 2 | 2025 | 840 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 627 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2021 | 824 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2090 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 3043 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2023 | 1258 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2024 | 872 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 399 | 0.070 |
Why?
|
| Zebrafish | 2 | 2020 | 420 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2021 | 615 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2020 | 789 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 1492 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 559 | 0.060 |
Why?
|
| Apolipoprotein A-V | 1 | 2024 | 23 | 0.060 |
Why?
|
| Lipoprotein Lipase | 1 | 2024 | 60 | 0.060 |
Why?
|
| Pyrenes | 1 | 2024 | 6 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2020 | 1005 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 145 | 0.060 |
Why?
|
| Cell Movement | 2 | 2021 | 920 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 57 | 0.050 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2023 | 15 | 0.050 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2023 | 19 | 0.050 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 81 | 0.050 |
Why?
|
| Neurons | 2 | 2025 | 2049 | 0.050 |
Why?
|
| Extremities | 1 | 2024 | 87 | 0.050 |
Why?
|
| Menarche | 1 | 2023 | 37 | 0.050 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2023 | 70 | 0.050 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2024 | 78 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 382 | 0.050 |
Why?
|
| Computers | 1 | 2023 | 71 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 401 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2023 | 34 | 0.050 |
Why?
|
| Incidence | 2 | 2021 | 3416 | 0.050 |
Why?
|
| Apoptosis | 2 | 2022 | 1946 | 0.050 |
Why?
|
| Physical Examination | 1 | 2023 | 165 | 0.050 |
Why?
|
| Microglia | 1 | 2023 | 139 | 0.050 |
Why?
|
| RecQ Helicases | 1 | 2022 | 64 | 0.050 |
Why?
|
| Dentate Gyrus | 1 | 2022 | 55 | 0.050 |
Why?
|
| MCF-7 Cells | 1 | 2022 | 233 | 0.050 |
Why?
|
| Bacteroides | 1 | 2022 | 37 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 182 | 0.050 |
Why?
|
| Triglycerides | 1 | 2024 | 617 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 406 | 0.050 |
Why?
|
| Spores, Fungal | 1 | 2021 | 14 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2023 | 377 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2023 | 189 | 0.050 |
Why?
|
| Air Microbiology | 1 | 2021 | 12 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 265 | 0.050 |
Why?
|
| Online Systems | 1 | 2021 | 17 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2022 | 152 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 363 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2023 | 779 | 0.040 |
Why?
|
| Endarterectomy | 1 | 2021 | 29 | 0.040 |
Why?
|
| Aminohydrolases | 1 | 2021 | 3 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2021 | 7 | 0.040 |
Why?
|
| Multifunctional Enzymes | 1 | 2021 | 6 | 0.040 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2021 | 13 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2021 | 27 | 0.040 |
Why?
|
| Pedigree | 1 | 2025 | 1712 | 0.040 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Fungi | 1 | 2021 | 75 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2022 | 145 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 1310 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 268 | 0.040 |
Why?
|
| Genes, Modifier | 1 | 2020 | 17 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 69 | 0.040 |
Why?
|
| Hormones | 1 | 2021 | 198 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2020 | 94 | 0.040 |
Why?
|
| Drosophila | 1 | 2025 | 829 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2022 | 303 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 115 | 0.040 |
Why?
|
| Metagenome | 1 | 2021 | 158 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2022 | 234 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Autophagy | 1 | 2023 | 429 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2022 | 577 | 0.040 |
Why?
|
| China | 1 | 2020 | 296 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 339 | 0.040 |
Why?
|
| Lansoprazole | 1 | 2019 | 28 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2024 | 940 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 334 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4807 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2019 | 22 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2024 | 414 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Tetracycline | 1 | 2019 | 79 | 0.040 |
Why?
|
| Schools | 1 | 2021 | 235 | 0.040 |
Why?
|
| Mastectomy | 1 | 2019 | 82 | 0.040 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2019 | 87 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 113 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1506 | 0.040 |
Why?
|
| Temperature | 1 | 2020 | 330 | 0.040 |
Why?
|
| Pregnancy | 2 | 2025 | 7570 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2019 | 127 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 198 | 0.040 |
Why?
|
| Metronidazole | 1 | 2019 | 157 | 0.040 |
Why?
|
| Karyotyping | 1 | 2019 | 324 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2019 | 125 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2021 | 364 | 0.040 |
Why?
|
| Mitosis | 1 | 2019 | 205 | 0.040 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2019 | 244 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2022 | 1433 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 1004 | 0.040 |
Why?
|
| Contig Mapping | 1 | 2018 | 56 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2018 | 56 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 453 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 756 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 276 | 0.040 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 211 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2018 | 220 | 0.030 |
Why?
|
| Body Composition | 1 | 2020 | 562 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 1012 | 0.030 |
Why?
|
| Chickens | 1 | 2018 | 640 | 0.030 |
Why?
|
| Exons | 1 | 2020 | 837 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 611 | 0.030 |
Why?
|
| Kidney | 1 | 2024 | 1421 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 139 | 0.030 |
Why?
|
| Chemokine CCL22 | 1 | 2017 | 6 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2018 | 169 | 0.030 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2017 | 6 | 0.030 |
Why?
|
| Species Specificity | 1 | 2018 | 571 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 645 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2017 | 37 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 609 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 1044 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 291 | 0.030 |
Why?
|
| Multigene Family | 1 | 2018 | 324 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 837 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 43 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1356 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2017 | 240 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 414 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 1338 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2017 | 103 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 322 | 0.030 |
Why?
|
| Chromosome Painting | 1 | 2016 | 18 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2021 | 1249 | 0.030 |
Why?
|
| Cicatrix | 1 | 2017 | 128 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 426 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2022 | 2301 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 752 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 263 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 789 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2016 | 136 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1200 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 703 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 785 | 0.030 |
Why?
|
| Alleles | 1 | 2020 | 1716 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1576 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 217 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 70 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 316 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 81 | 0.030 |
Why?
|
| Dasatinib | 1 | 2014 | 50 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 481 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2017 | 402 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2172 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2266 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 563 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2014 | 143 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 1039 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 104 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2019 | 1027 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1146 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 201 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 256 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 440 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 303 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 249 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 300 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 254 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3754 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 403 | 0.030 |
Why?
|
| Cisplatin | 1 | 2014 | 287 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 262 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2020 | 1626 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 352 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 282 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 2997 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1190 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 842 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6601 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2860 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2198 | 0.020 |
Why?
|
| Child | 2 | 2023 | 25870 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 3187 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 746 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2014 | 418 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2023 | 3178 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 2175 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 797 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 825 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6610 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 4878 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2578 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1853 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 20609 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 9935 | 0.010 |
Why?
|